The Biopharmaceutical Development Program (BDP) produces novel antibodies and proteins as therapeutics when industry is not prepared to develop them.
For example, when the Children’s Oncology Group could not find a manufacturer to produce ch14.18, a monoclonal antibody being evaluated as a treatment
for neuroblastoma tumors in children, BDP manufactured the antibody for the clinical trial. The trial demonstrated that ch14.18 reduced the risk of
recurrence when given to children whose cancer responded to chemotherapy. The monoclonal antibody has become the standard of care for children with
certain types of neuroblastoma, and the pharmaceutical company United Therapeutics is now manufacturing the antibody.
Typed the characters seen in the image below to continue.
Sending Mail ...